John G. Clohessy

The paper shows that oncogene-imposed dosage constraints can lead to mutations resembling tumor suppressor loss, which are essential in APL.

This study identifies a metabolic-epigenetic mechanism linking leucine catabolism to glycolysis that drives resistance to CDK4/6 inhibitors in ER+ breast cancer.

This study identifies BRD2 as a co-targetable vulnerability with PI3K/AKT inhibitors in breast cancer, showing that BRD2 phosphorylation is required for chromatin binding and that targeting BRD2 enhances drug efficacy.

ProMPt is a syngeneic mouse platform modeling prostate cancer heterogeneity, revealing MYC's role in progression and showing that MAPK inhibition plus translation blockade synergistically suppresses castration-resistant tumors.

This study identifies a new IMiD-independent drug targeting SALL4's ZFC4 domain, leading to significant tumor growth inhibition in vivo.

This study identifies NDRG1 as a DNA repair protein that links pancreatic cancer stroma to chemoresistance by enhancing DNA damage repair through R-loop resolution.

This study identifies a synergistic effect between AKT inhibitors and pitavastatin in killing triple-negative breast cancer cells by targeting cholesterol trafficking.

This study compares shRNA and CRISPR/Cas13d screens for circRNA function, finding that optimized CRISPR/Cas13d reduces false positives and identifies true functional circRNAs.

This paper demonstrates that pancreatic tumor organoids (PDOs) recapitulate PDX models' features and can identify clinically-actionable biomarkers in blood.